Estrogens, such as DES and E2 given at high doses (1.5–1500 mg/day), had been used to treat ER-positive advanced breast cancer until the introduction of tamoxifen,82–86 an ER antagonist in breast tissue. This evidence concerns the gene ESR1 and breast carcinoma.